Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option

Executive Summary

Fitusiran's mechanism of reducing antithrombin levels could apply to all hemophilia patients, as well as those with other rare bleeding disorders. Reducing antithrombin increases thrombin levels and helps to increase normal clotting.

Advertisement

Related Content

Competition Coming For Hemophilia Franchises, But Will Patients And Payers Embrace New Drugs?
Alnylam's 'Day After' Revusiran Failure Bad, Maybe Not Catastrophic
Alnylam Ends Revusiran In Phase III, But Was Failure Due To Safety Or Efficacy?
Biogen Hemophilia Spin Out Bioverativ On Track For Early 2017
Shire Backs Hemophilia Focus With Asset Updates, Irish iPATH Study
Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work
Hemophilia Market Snapshot: Is There Enough Innovation For Patients To Switch?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097184

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel